From the prodromal stage of multiple sclerosis to disease prevention.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Marrie Ruth Ann, Allegretta Mark, Barcellos Lisa F, Bebo Bruce, Calabresi Peter A, Correale Jorge, Davis Benjamin, De Jager Philip L, Gasperi Christiane, Greenbaum Carla, Helme Anne, Hemmer Bernhard, Kanellis Pamela, Kostich Walter, Landsman Douglas, Lebrun-Frenay Christine, Makhani Naila, Munger Kassandra L, Okuda Darin T, Ontaneda Daniel, Postuma Ronald B, Quandt Jacqueline A, Roman Sharon, Saidha Shiv, Sormani Maria Pia, Strum Jon, Valentine Pamela, Walton Clare, Zackowski Kathleen M, Zhao Yinshan, Tremlett Helen
Аннотация
A prodrome is an early set of signs or symptoms that indicate the onset of a disease before more typical symptoms develop. Prodromal stages are well recognized in some neurological and immune-mediated diseases such as Parkinson disease, schizophrenia, type 1 diabetes mellitus and rheumatoid arthritis. Emerging evidence indicates that a prodromal stage exists in multiple sclerosis (MS), raising the possibility of intervention at this stage to delay or prevent the development of classical MS. However, much remains unclear about the prodromal stage of MS and considerable research is needed to fully characterize the prodrome and develop standardized criteria to reliably identify individuals with prodromal MS who are at high risk of progressing to a diagnosis of MS. In this Roadmap, we draw on work in other diseases to propose a disease framework for MS that incorporates the prodromal stage, and set out key steps and considerations needed in future research to fully characterize the MS prodrome, identify early disease markers and develop standardized criteria that will enable reliable identification of individuals with prodromal MS, thereby facilitating trials of interventions to slow or stop progression beyond the prodrome.